profit from every $100 of sales.
$0$100
Veru
$2.14+0.94% today
-18.3% in 1 year
1-year low $2.061-year high $4.23
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2023.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Veru sold, what it kept, and what it did with the cash.
Sales went from $39.4 million in 2022 to $0 in 2025, with -$22.7 million of profit last year.
SalesProfit
Veru vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Veru | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Veru's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 39 | 16 | 0 | 0 | |
| 31 | 8 | 6 | – | |
| -83 | -96 | -37 | -36 | |
| -79 | -90 | -37 | -35 | |
| -84 | -93 | -38 | -23 | |
| -10.50 | -11.00 | -2.80 | -1.55 | |
| 77.7% | 46.4% | – | – | |
| -212.1% | -586.6% | – | – | |
| -213.5% | -571.6% | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 135 | 50 | 60 | 30 |
| Cash | 80 | 10 | 25 | 16 |
| Total debt | 16 | 14 | 14 | 3 |
| Total liabilities | 53 | 30 | 28 | 12 |
| 83 | 20 | 32 | 18 | |
| 8 | 8 | 13 | 15 | |
| -63.6% | -209.2% | -64.4% | -130.9% | |
| -101.5% | -473.4% | -117.0% | -124.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -48 | -88 | -22 | -30 | |
| 1 | 1 | 0 | 0 | |
| -48 | -89 | -22 | -30 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 11 | 18 | 14 | 8 |
Valuation
- –
- –
- –
- 1.2×
- 2.2×
- –
- –
- -243.0%
- -255.3%
- 0.0%
Profitability
- 46.4%
- -586.6%
- -571.6%
- -4,066.1%
- -48.4%
- -108.3%
- -83.2%
- -40.2%
- -49.3%
- 4,539.5%
Growth
- −58.6%
- –
- −37.6%
- –
- +17.7%
Financial health
- –
- 0.08
- 6.3%
- –
- 5.16
- 5.16
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 7%of 958
Bottom 1%of 889
What analysts expect
- Average price target
- $4.00
- Range
- $3.00 – $5.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.13 | -0.31 | +58.1% |
| Feb 11, 2026 | -0.26 | -0.47 | +44.7% |
| Dec 17, 2025 | -0.60 | -0.37 | −64.4% |
| Aug 12, 2025 | -0.50 | -0.55 | +9.1% |
| May 8, 2025 | -0.05 | -0.06 | +16.7% |
| Feb 13, 2025 | -0.07 | -0.08 | +12.5% |
| Dec 16, 2024 | -0.06 | -0.07 | +14.3% |
| Aug 8, 2024 | -0.07 | -0.06 | −16.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
43No pass
Benjamin Graham
68Pass
Philip Fisher
44No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
46No pass
Terry Smith
46No pass
Questions about Veru
Is Veru a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Veru AI analysis
What does Veru do?
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. It is in Biotechnology.
Does Veru pay a dividend?
No. Veru does not pay a dividend at the moment.
Is Veru stock halal?
No. Veru does not pass our halal screen: its cash and confirmed interest-bearing investments are 43% of its market value, at or above the 33% limit. How we check
How has Veru stock done over the past year?
Down 18.3% over the past twelve months, to $2.14. It traded between $2.06 and $4.23 and is 49.4% below its high.
Who are Veru's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Veru's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.